Webinar Date/Time: Wed, Jul 16, 2025 11:00 AM EDT
Did you know that the first charged aerosol detector (CAD) was introduced in 2005? Join Frank Steiner, PhD, and Paul Gamache, MS, one of the original inventors, for the webinar Celebrating 20 Years of HPLC-CAD Technology.
Register Free: https://www.biopharminternational.com/bp_w/HPLC-CAD-Technology
Event Overview:
Did you know that the first charged aerosol detector (CAD) was introduced in 2005? Now 2 decades later, this near-universal detector is an essential part of the analytical chemist’s quantitative toolbox. Join Frank Steiner, PhD, and Paul Gamache, MS, one of the original inventors, for a webinar celebrating 20 years of HPLC-CAD technology. This seminar will cover the history of the invention, when the detector found a place for everyday use by separation scientists, and how the CAD compares to ELSD. More technical parts of the talk will showcase why detector settings like the evaporation temperature drive application versatility, and how the power function affects linearity and response curves.
Key Learning Objectives:
Speaker:
Frank Steiner, PhD
Senior Manager, Product
Applications
Thermo Fisher Scientific
Frank Steiner, PhD, is the senior manager of product applications and helps coordinate scientific collaborations at Thermo Fisher Scientific as a scientific advisor for HPLC. He received his PhD in analytical chemistry in 1995 from Saarland University in Saarbrücken, Germany, and has had more than 30 works published in refereed journals and more than 10 textbook chapters published on HPLC topics.
Speaker's Email: frank.steiner@thermofisher.com
Paul Gamache, MS
Independent Consultant, Liquid
Chromatography
Self-Employed
Paul Gamache, MS, is a highly respected scientist, inventor, publisher, and technical consultant. His professional successes include the development of analytical technologies with a primary focus on charged aerosol detection and electrochemical detection for LC analysis, along with the design and launch of the first- and second-generation Corona CAD products.
Register Free: https://www.biopharminternational.com/bp_w/HPLC-CAD-Technology
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.